Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AMRX
Strong BuyPremium GrowerFLAGAmneal Pharmaceuticals, Inc. · Healthcare · United States · $6.1B · Avg Vol: $31M/d
Amneal Pharmaceuticals has strong momentum at M81 and quality Q65, but value at V38 is below the calibrated floor, so stage one fails. Insider selling is separately adverse.
COMPANY DESCRIPTION
Amneal Pharmaceuticals, Inc. is a U.S. pharmaceutical company engaged in the development, manufacturing, and distribution of a broad portfolio of generic and specialty pharmaceutical products. The company's competitive strength lies in its expansive generic pipeline, efficient manufacturing infrastructure, and a growing presence in complex generics, biosimilars, and specialty branded products. This diversified approach allows it to address a wide range of therapeutic areas and market opportunities.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.2B | 2.4B | 2.8B | 3.0B | 10.9% | 3.1B | 3.2B | 3.4B | 6.6% |
| EPS | -0.41 | -0.48 | -0.38 | 0.23 | — | 0.48 | 0.28 | 0.32 | 18.3% |
| Shares | 319.3M | 306.6M | 309.9M | 314.6M | -1.5% | 348.3M | — | — | — |
| Debt | 2.8B | 2.8B | 2.6B | 2.7B | -1.9% | 2.8B | — | — | — |
| Equity | 298.4M | 19.8M | -109.3M | -70.8M | -93.4% | — | — | — | — |
| Op CF | 65.1M | 345.6M | 295.1M | 340.0M | 73.5% | 200.8M | — | — | — |
| Inv CF | -174.3M | -69.2M | -63.0M | -112.3M | — | — | — | — | — |
| Fin CF | -106.6M | -212.6M | -211.8M | -31.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AMRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AMRX | Amneal Pharmaceuticals, Inc.(you) | $6.1B | 83 | Strong Buy |
| LNTH | Lantheus Holdings, Inc. | $6.6B | 88 | Strong Buy |
| LQDA | Liquidia Corporation | $6.1B | 64 | Hold |
| INDV | Indivior Pharmaceuticals, Inc. | $4.1B | 94 | Strong Buy |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.5B | 85 | Strong Buy |
| NBIX | Neurocrine Biosciences, Inc. | $15.7B | 85 | Strong Buy |
| VTRS | Viatris Inc. | $18.8B | 86 | Strong Buy |
| ELAN | Elanco Animal Health Incorporated | $12.0B | 70 | Buy |
| TRLV | Trulieve Cannabis Corp. | $2.3B | 90 | Strong Buy |
| UTHR | United Therapeutics Corporation | $22.1B | 85 | Strong Buy |
Peer medians: ROE -30.8% · P/E 26.9x · Gross margin 58.3%